Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 140 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015', provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview 8
Therapeutics Development 9
Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Overview 9
Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 10
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 11
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 16
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 18
Advaxis, Inc. 18
Amgen Inc. 19
AVEO Pharmaceuticals, Inc. 20
Critical Outcome Technologies Inc. 21
Daiichi Sankyo Company, Limited 22
Genentech, Inc. 23
Glycotope GmbH 24
Immunovative Therapies, Ltd. 25
Laboratoires Pierre Fabre SA 26
Mabion SA 27
MedImmune, LLC 28
Merck & Co., Inc. 29
Novartis AG 30
Oncolytics Biotech Inc. 31
Ono Pharmaceutical Co., Ltd. 32
Panacea Biotec Limited 33
PCI Biotech AS 34
Shionogi & Co., Ltd. 35
Symphogen A/S 36
VentiRx Pharmaceuticals, Inc. 37
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
ADXS-HPV - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AlloVax - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
alpelisib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
bleomycin sulfate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
cetuximab biobetter - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
cetuximab biosimilar - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
cetuximab biosimilar - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
cetuximab biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
COTI-2 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
duligotuzumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
durvalumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
durvalumab + tremelimumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ficlatuzumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
futuximab - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
LJM-716 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
motolimod - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
nivolumab - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
patritumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pelareorep - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
pembrolizumab - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
S-488210 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
vinflunine ditartrate - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 98
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 137
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 138
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 139
Disclaimer 140

List of Tables
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H1 2015 9
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H1 2015 18
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H1 2015 19
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 20
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H1 2015 21
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 22
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech, Inc., H1 2015 23
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H1 2015 24
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H1 2015 25
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 26
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H1 2015 27
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2015 28
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2015 29
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H1 2015 30
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H1 2015 31
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 32
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2015 33
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H1 2015 34
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H1 2015 35
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H1 2015 36
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 37
Assessment by Monotherapy Products, H1 2015 38
Assessment by Combination Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 47
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2015 98
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H1 2015 137
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H1 2015 138